BI-685509
Modify Date: 2025-08-24 10:20:28
BI-685509 structure
|
Common Name | BI-685509 | ||
|---|---|---|---|---|
| CAS Number | 1579514-06-9 | Molecular Weight | 582.69 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C34H38N4O5 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of BI-685509BI-685509 is a potent and orally active sGC activator. BI-685509 restores cyclic guanosine monophosphate (cGMP) and improves functionality of nitric oxide (NO) pathways. BI-685509 can be used in research of chronic kidney disease (CKD) and diabetic kidney disease (DKD)[1]. |
| Name | BI-685509 |
|---|
| Description | BI-685509 is a potent and orally active sGC activator. BI-685509 restores cyclic guanosine monophosphate (cGMP) and improves functionality of nitric oxide (NO) pathways. BI-685509 can be used in research of chronic kidney disease (CKD) and diabetic kidney disease (DKD)[1]. |
|---|---|
| Related Catalog | |
| In Vitro | BI 685509 在用血红素氧化剂 ODQ (HY-101255) 处理的人和大鼠富含血小板的血浆中增加 cGMP，EC50 值分别为 467 nM 和 304 nM[1]。 |
| In Vivo | BI 685509 (1, 3, 10, 30 mg/kg; p.o.) 与 Enalapril (HY-B0331) 共同给药以剂量依赖性方式降低蛋白尿和肾小球硬化的发生率[1]。 BI 685509 (30 mg/kg; p.o.) 减少大鼠单侧输尿管梗阻 (UUO) 模型中的肾小管间质纤维化[1]。 Animal Model: ZSF1 rat model[1] Dosage: 1, 3, 10, 30 mg/kg; 3 mg/kg (enalapril) Administration: Oral administration; daily Result: Reduced proteinuria and incidence of glomerular sclerosis in a dose-dependent manner. Animal Model: rat UUO model[1] Dosage: 30 mg/kg Administration: v Result: Reduced tubulointerstitial fibrosis in rat UUO model. |
| References |
| Molecular Formula | C34H38N4O5 |
|---|---|
| Molecular Weight | 582.69 |